ストックスクリーナーアプリを入手
0.96
0.41%
-0.004
アフターアワーズ：
.90
-0.06
-6.25%
Silexion Therapeutics Corp (SLXN) 最新ニュース
Silexion reports breakthrough in KRAS-driven cancer therapy By Investing.com - Investing.com Nigeria
Silexion reports breakthrough in KRAS-driven cancer therapy - Investing.com Australia
Silexion Therapeutics Announces Groundbreaking Preclinical Results: SIL204 Shows Strong Efficacy in Pancreatic, Colorectal, and Lung Cancers - The Manila Times
Silexion Therapeutics Announces Groundbreaking Preclinical - GlobeNewswire
Revolutionary Cancer Drug Shows 90% Inhibition Rate Against Pancreatic, Lung, and Colorectal Cancers in New Study - Stock Titan
Reviewing Silexion Therapeutics (NASDAQ:SLXN) & BioNTech (NASDAQ:BNTX) - Defense World
Silexion Therapeutics Receives Nasdaq Delisting Notice - TipRanks
PESG Research Report: A Review of Silexion Therapeutics' Innovative KRAS-Driven Cancer Treatment - TradingView
Silexion's SIL204 Completes Key Preclinical Studies In KRAS-Mutant Cancers - Nasdaq
Silexion Therapeutics Completes Key Preclinical Studies Exploring Sil204's Potential Impact on Colorectal and Lung Cancer - marketscreener.com
Silexion Completes Key Preclinical Studies for SIL204 - TipRanks
Silexion Therapeutics Completes Key Preclinical Studies - GlobeNewswire
Major Cancer Treatment Advance: Silexion's RNAi Drug Shows Promise Against 3 Deadly Cancers in $30B Market - Stock Titan
Form 424B3 Silexion Therapeutics - StreetInsider
Silexion Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Update - marketscreener.com
Silexion Therapeutics Reports Q1 2025 Financial Results and Key Developments in RNAi Cancer Therapy - Nasdaq
Silexion Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
SLXNSilexion Therapeutics Corp Latest Stock News & Market Updates - Stock Titan
Is Silexion Therapeutics Corp (SLXN) positioned for future growth? - Sete News
Silexion Therapeutics Partners with Catalent to Advance Revolutionary KRAS-Targeting Cancer Therapy - citybuzz -
Silexion Therapeutics partners with Catalent for cancer drug development By Investing.com - Investing.com South Africa
SLXN’s price-to-sales ratio: Is it a good investment opportunity? - uspostnews.com
Silexion Partners With Catalent To Advance SIL204 SiRNA Therapy For KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Partners with Catalent for SIL204 Development - TipRanks
Silexion Therapeutics partners with Catalent for cancer drug development - Investing.com Australia
Silexion Therapeutics enters collaboration with Catalent - TipRanks
Silexion Therapeutics Announces Collaboration with Global Therapeutics Leader Catalent on Advanced siRNA Formulation Development & Clinical Manufacturing Activities - The Manila Times
Silexion Therapeutics Enters Strategic Collaboration with Catalent to Advance SIL204 Development for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Announces Collaboration with Global - GlobeNewswire
Major Breakthrough: Silexion's Multi-KRAS Cancer Drug Enters Manufacturing Phase with Industry Giant Catalent - Stock Titan
Titan Pharmaceuticals (NASDAQ:TTNP) and Silexion Therapeutics (NASDAQ:SLXN) Head to Head Review - Defense World
Silexion plans dual-route strategy for SIL-204 for KRAS-driven pancreatic cancer - BioWorld MedTech
Buy Rating for Silexion Therapeutics Driven by Promising SIL-204 Developments and Market Expansion - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy By Investing.com - Investing.com South Africa
Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical Data - markets.businessinsider.com
Silexion Therapeutics Unveils Innovative Expanded - GlobeNewswire
Silexion Therapeutics announces expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Expands SIL204 Development Plan - TipRanks
Silexion advances dual-route strategy for KRAS cancer therapy - Investing.com
Silexion Therapeutics Corp Unveils Expanded Development Plan For Sil204 - MarketScreener
Game-Changing Cancer Treatment: Silexion's New Dual-Action Drug Targets Both Primary Tumors and Metastases - Stock Titan
Maxim Group Cuts Silexion Therapeutics (NASDAQ:SLXN) Price Target to $5.00 - Defense World
Silexion Therapeutics price target lowered to $5 from $9 at Maxim - MSN
Silexion announces completion of expanded development plan for SIL204 - TipRanks
Silexion Therapeutics Corp. Announces Expanded Development Plan for SIL204 at NeauxCancer 2025 Conference - Nasdaq
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference - GlobeNewswire
Revolutionary KRAS Cancer Treatment: Silexion Expands Development Strategy for SIL204 - StockTitan
Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Silexion Therapeutics Corp. Reports 2024 Financial Results and Progress on SIL204 for KRAS-Driven Cancers - Nasdaq
Silexion Therapeutics Corp SEC 10-K Report - TradingView
Revolutionary Cancer Drug SIL204 Tackles Both Primary Tumors and Metastasis with 80% Success Rate - StockTitan
Silexion Therapeutics reaches deal to retire convertible note - Investing.com
Silexion Therapeutics Receives Buy Rating from Naz Rahman Following Promising SIL-204 Pre-Clinical Results - TipRanks
Silexion Therapeutics (NASDAQ: SLXN) Announces Path-Breaking Data for SIL204: Stock Soars 30% - DRP Journal
0.95%
大文字化:
|
ボリューム (24 時間):